Search - tctmd.com

Displaying 161 - 180 of 402

Sort: Relevancy | Date

Presentation TCT 2016

Are PCSK9 Inhibitors and Anti-inflammatory Therapies for Vulnerable Plaque Right Around the Corner?

Presenter: Gregg W. Stone, Ron Waksman, Sanjit S. Jolly

November 01, 2016

Presentation TCT 2016

To Treat or Not to Treat (Focally): From Stable to PROSPECT-ABSORB and PREVENT

Presenter: Gregg W. Stone, Ron Waksman, Seung-Jung Park

November 01, 2016

Presentation TCT 2016

Bioresorbable Scaffolds for Vulnerable Plaque Treatment: Rationale for Focal Therapy, Early Clinical Experiences, and Will it Succeed?!

Presenter: Gregg W. Stone, Ron Waksman, Vasim Farooq

November 01, 2016

Presentation TCT 2016

Case Conclusion: How Did We Revascularize This Patient?

Presenter: John D. Puskas, Gregg W. Stone, Michael E. Halkos

November 01, 2016

Presentation TCT 2016

Case Introduction: How Would You Revascularize This Patient?

Presenter: John D. Puskas, Gregg W. Stone, Michael E. Halkos

November 01, 2016

Presentation TCT 2016

Announcing the NIH-sponsored HYBRID Revascularization Trial

Presenter: John D. Puskas, Gregg W. Stone

November 01, 2016

Presentation TCT 2016

Hybrid Coronary Revascularization: Results to Date (From Meta-analysis to the NIH Multicenter Observational Study)

Presenter: John D. Puskas, Gregg W. Stone

November 01, 2016

Presentation TCT 2016

Hybrid Coronary Revascularization: Rationale, Procedure Alternatives, and Technical Considerations

Presenter: John D. Puskas, Gregg W. Stone, John S. Douglas Jr

November 01, 2016

Presentation TCT 2016

PARTNER I FIVE-YEAR ECHO: Long-term Hemodynamic and Structural Outcomes After Transcatheter Aortic Valve Replacement in High-Risk and Inoperable Patients With Aortic Stenosis

Presenter: Gregg W. Stone, Philippe Pibarot, Pamela S. Douglas

November 01, 2016

Presentation TCT 2016

PARTNER II QUALITY OF LIFE: Health Status Benefits From a Prospective, Randomized Trial of Transcatheter and Surgical Aortic Valve Replacement in Intermediate-Risk Patients With Severe Aortic Stenosis

Presenter: Gregg W. Stone, Philippe Pibarot, David J. Cohen

November 01, 2016

Presentation TCT 2016

SENTINEL: A Prospective, Randomized Trial Evaluating Cerebral Protection in Patients With Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement

Presenter: Gregg W. Stone, Philippe Pibarot, Susheel K. Kodali

November 01, 2016

Presentation TCT 2016

When There Are No Revascularization Options: Indications and Evidence for the Coronary Sinus Reducer in the CHIP Patient

Presenter: Jonathan M. Hill, Dimitri Karmpaliotis, Gregg W. Stone

October 31, 2016

Presentation TCT 2016

Benefit of Supersaturated Oxygen for Large Anterior STEMI: From ICI-HOT to Approval?

Presenter: Cindy L. Grines, Holger Thiele, Gregg W. Stone

October 31, 2016

Presentation TCT 2016

EXCEL Top Line Results Revisited

Presenter: A. Pieter Kappetein, Marie-Claude Morice, Gregg W. Stone

October 31, 2016

Presentation TCT 2016

Key Note Lecture II. Regulatory Reform of Medical Device Approvals by the European Commission Motivating Factors, Anticipated Changes, and Timelines

Presenter: Matthew G. Hillebrenner, Gregg W. Stone, Alan G. Fraser

October 31, 2016

Presentation TCT 2016

Key Note Lecture I. FDA/CDRH State of the Union

Presenter: Matthew G. Hillebrenner, Gregg W. Stone, Jeffrey Shuren

October 31, 2016

Presentation TCT 2016

The FDA Town Hall Meeting: Evolution of a Decades Long Collaboration Between Physician-Scientists, Industry, Regulators, and Payors

Presenter: Matthew G. Hillebrenner, Gregg W. Stone

October 31, 2016

News Conference News TCT 2016

EXCEL y NOBLE: Los Resultados Contrarios Plantean un Dilema a la Hora de Elegir entre PCI y CABG en el Manejo de la Enfermedad de Tronco Coronario Izdo.

Michael O'Riordan

October 31, 2016

News Conference News TCT 2016

EXCEL and NOBLE: Opposing Results Pose Quandary for PCI/CABG Choice in Left Main Disease

Michael O'Riordan

October 31, 2016

Presentation TCT 2016

EXCEL: A Prospective, Randomized Trial Comparing Everolimus-Eluting Stents and Bypass Graft Surgery in Selected Patients With Left Main Coronary Artery Disease

Presenter: Martin B. Leon, Keith G. Oldroyd, Gregg W. Stone

October 31, 2016

Advertisement

Are PCSK9 Inhibitors and Anti-inflammatory Therapies for Vulnerable Plaque Right Around the Corner?

To Treat or Not to Treat (Focally): From Stable to PROSPECT-ABSORB and PREVENT

Bioresorbable Scaffolds for Vulnerable Plaque Treatment: Rationale for Focal Therapy, Early Clinical Experiences, and Will it Succeed?!

Case Conclusion: How Did We Revascularize This Patient?

Case Introduction: How Would You Revascularize This Patient?

Announcing the NIH-sponsored HYBRID Revascularization Trial

Hybrid Coronary Revascularization: Results to Date (From Meta-analysis to the NIH Multicenter Observational Study)

Hybrid Coronary Revascularization: Rationale, Procedure Alternatives, and Technical Considerations

PARTNER I FIVE-YEAR ECHO: Long-term Hemodynamic and Structural Outcomes After Transcatheter Aortic Valve Replacement in High-Risk and Inoperable Patients With Aortic Stenosis

PARTNER II QUALITY OF LIFE: Health Status Benefits From a Prospective, Randomized Trial of Transcatheter and Surgical Aortic Valve Replacement in Intermediate-Risk Patients With Severe Aortic Stenosis

SENTINEL: A Prospective, Randomized Trial Evaluating Cerebral Protection in Patients With Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement

When There Are No Revascularization Options: Indications and Evidence for the Coronary Sinus Reducer in the CHIP Patient

Benefit of Supersaturated Oxygen for Large Anterior STEMI: From ICI-HOT to Approval?

EXCEL Top Line Results Revisited

Key Note Lecture II. Regulatory Reform of Medical Device Approvals by the European Commission Motivating Factors, Anticipated Changes, and Timelines

Key Note Lecture I. FDA/CDRH State of the Union

The FDA Town Hall Meeting: Evolution of a Decades Long Collaboration Between Physician-Scientists, Industry, Regulators, and Payors

EXCEL y NOBLE: Los Resultados Contrarios Plantean un Dilema a la Hora de Elegir entre PCI y CABG en el Manejo de la Enfermedad de Tronco Coronario Izdo.

EXCEL and NOBLE: Opposing Results Pose Quandary for PCI/CABG Choice in Left Main Disease

EXCEL: A Prospective, Randomized Trial Comparing Everolimus-Eluting Stents and Bypass Graft Surgery in Selected Patients With Left Main Coronary Artery Disease

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content